RayKnowChina Research Map
Shortlist

Nantong University

南通大学

NantongUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.8%Leads under 1 in 100 of China's research papers on NPC

Led 20 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
1
Research papers it led
20
Trials it led
2
Share of China's trials
0.3%
Share of the world's papers
0.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesRecurrent / metastatic diseaseInduction / concurrent chemotherapy

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Nantong University20

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.8%Leads under 1 in 100 of China's research papers on ESCC

Led 22 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
0
Research papers it led
22
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025
ThemesMolecular markers & genomicsImaging & AIImmunotherapy

Hospitals counted here

  1. Affiliated Hospital of Nantong University22

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
1.0%Leads under 1 in 100 of China's research papers on HCC

Led 145 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
0
Research papers it led
145
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Nantong University145

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Using pre-operative radiomics to predict microvascular invasion of hepatocellular carcinoma based on Gd-EOB-DTPA enhanced MRI.2022BMC medical imagingRCTFree full text
  2. Outcomes of laparoscopic versus open liver resection in patients with large or huge HCC: a multicenter study.2026Surgical endoscopy
  3. A multicenter case-controlled study on laparoscopic hepatectomy versus open liver resection as first-line therapy for solitary hepatocellular carcinoma in elderly patients.2026Surgical endoscopy
  4. Prediction of PD-1 Expression and Outcomes of Combined Therapy in Hepatocellular Carcinoma: an MRI-Based Radiomics Approach.2026Journal of imaging informatics in medicineFree full text
  5. Significance of anatomical resection and wide surgical margin for HCC patients with MVI undergoing laparoscopic hepatectomy: A multicenter study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Trials on ClinicalTrials.gov3
  1. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  2. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  3. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
1.1%Leads about 1 in 92 of China's research papers on Stomach cancer

Led 107 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
1
Research papers it led
107
Trials it led
2
Share of China's trials
0.1%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 222025
ThemesPeritoneal spread & advanced diseaseSurgeryEarly detection & endoscopy

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Nantong University107

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Clinical Effect of Tumor-Specific Total Nutrients in Patients with Adjuvant Chemotherapy After Radical Gastric Cancer Resection: A Randomized Controlled Trial.2024Journal of gastrointestinal cancerRCTFree full text
  2. Effect of bilateral paravertebral nerve block on cognitive function in elderly patients undergoing radical gastrectomy for gastric cancer: a prospective randomized double-blind controlled trial.2022BMC anesthesiologyRCTFree full text
  3. The effects of video based nursing education on perioperative anxiety and depression in patients with gastric cancer.2021Psychology, health & medicineRCT
  4. Nociceptive neurons promote gastric tumour progression via a CGRP-RAMP1 axis.2025NatureFree full text
  5. Development and validation of a diagnostic and screening method for gastric cancer by combining new gastric cancer screening score and serum biomarkers: a prospective study.2025BMC cancerFree full text
Trials on ClinicalTrials.gov5
  1. Screening of Small Non-coding RNAs as an Auxiliary Diagnostic Biomarker for Gastric CancerEnrolling by invitationNCT06776835Lead sponsorStart 2023-12
  2. Laparoscopic Gastric Function Preserving Surgery Combined With Resection of the Anterior Lymphatic Drainage AreaStatus unknownNCT05160753Lead sponsorN/AStart 2022-01
  3. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  4. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04
  5. A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Study sitePhase 2/Phase 3Start 2012-09

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
0.4%Leads under 1 in 100 of China's research papers on Osteosarcoma

Led 9 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
9
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Nantong University9

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
0.6%Leads under 1 in 100 of China's research papers on Gastrointestinal stromal tumour ▼ from 1.3%

Led 3 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Affiliated Hospital of Nantong University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
0.9%Leads under 1 in 100 of China's research papers on Neuroblastoma

Led 10 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
1
Share of China's trials
2.4%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 3320242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Nantong University10

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
0.9%Leads under 1 in 100 of China's research papers on Myeloma ▼ from 3.7%

Led 16 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
1
Research papers it led
16
Trials it led
2
Share of China's trials
0.4%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 332025
ThemesDiagnosis, MRD & riskDrug combinationsRelapse & resistance

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Affiliated Hospital of Nantong University16

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effect of Bortezomib Treatment in Multiple Myeloma on Blood Coagulation Function, Renal Function, Immune Function, and the NF-κB Pathway-Associated Indicators.2025British journal of hospital medicine (London, England : 2005)
  2. Bortezomib-based chemotherapy for patients with Waldenström macroglobulinemia: a single-center experience.2023Annals of hematology
  3. The Causal Relationship between Lipid Metabolites and Multiple Myeloma Risk: A Mendelian Randomization Study.2026Acta haematologica
  4. Single-cell and bulk transcriptomics uncovers PRKD2-driven tumor stemness and progression in multiple myeloma.2025Scientific reportsFree full text
  5. NAT10 contributes to the progression of multiple myeloma through ac4C modification of GPR37.2025Hematology (Amsterdam, Netherlands)
Trials on ClinicalTrials.gov6
  1. Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple MyelomaRecruitingNCT06246162Lead sponsorPhase 1/Phase 2Start 2023-11
  2. Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT07663253Study siteStart 2026-06
  3. A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple MyelomaRecruitingNCT06497738Study siteStart 2024-05
  4. The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma PatientsStatus unknownNCT05802992Lead sponsorPhase 3Start 2022-03
  5. SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary DiseaseCompletedNCT05900882Study sitePhase 2Start 2022-07
  6. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
0.5%Leads under 1 in 100 of China's research papers on Aplastic anaemia

Led 2 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025
ThemesThrombopoietin drugsImmunosuppressive treatment

Hospitals counted here

  1. Affiliated Hospital of Nantong University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
0.8%Leads under 1 in 100 of China's research papers on HLH New since 2021

Led 3 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 002025
ThemesLymphoma & cancer-related HLHDiagnosis & prognosisTreatment regimens

Hospitals counted here

  1. Affiliated Hospital of Nantong University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
0.4%Leads under 1 in 100 of China's research papers on Idiopathic pulmonary fibrosis

Led 4 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 222025

Hospitals counted here

  1. Affiliated Hospital of Nantong University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
0.6%Leads under 1 in 100 of China's research papers on Amyotrophic lateral sclerosis

Led 5 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.08%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 2220242025: 222025

Hospitals counted here

  1. Affiliated Hospital of Nantong University5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
0.9%Leads under 1 in 100 of China's research papers on Duchenne muscular dystrophy New since 2021

Led 2 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.08%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. Affiliated Hospital of Nantong University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
0.1%Leads under 1 in 100 of China's research papers on IgA nephropathy

Led 1 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.06%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

Hospitals counted here

  1. Affiliated Hospital of Nantong University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led1
  1. Identification of key necroptosis-related genes and immune landscape in patients with immunoglobulin A nephropathy.2024BMC nephrology
Trials on ClinicalTrials.gov3
  1. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  2. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
0.7%Leads under 1 in 100 of China's research papers on Primary biliary cholangitis

Led 2 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Affiliated Hospital of Nantong University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov